Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure

作者：Trachana Maria^*; Pratsidou Gertsi Polyxeni; Badouraki Maria; Haidich Anna Bettina; Pardalos Grigoris

来源：Clinical Rheumatology, 2013, 32(8): 1191-1197.

DOI：10.1007/s10067-013-2261-z

• Associations
• Clinical remission
• Etanercept
• Juvenile arthritis disease activity score
• Juvenile idiopathic arthritis

The objective of this retrospective study was to record the achievement of clinical remission (CR) in juvenile idiopathic arthritis patients under a 2-10 years%26apos; administration of Etanercept (ETN) and to detect any variables associated with CR. Patients previously resistant to conventional regimens were enrolled. The annual impact of ETN was assessed by: (a) the American College of Rheumatology pediatric criteria (ACRpedi), (b) the pre- and posttreatment disease activity score (juvenile arthritis disease activity score [JADAS71]), and (c) Wallace%26apos;s criteria for CR. A total of 41 patients (F: 31) were registered. The median age and disease duration at baseline were 10.6 and 4.17 years, respectively, and their disease course was mainly polyarthritis (32/41). In respect to baseline, there was an impressive JADAS71 reduction posttreatment, most prominent after the first year. From year 1 to 5, more than 50 % of the patients achieved and retained CR and 66 % reached an ACRpedi 70, whereas after the 5th year, no patient was withdrawn due to an ACRpedi %26lt; 30. JADAS71 at baseline was not associated with the subsequent CR achievement. However, JADAS71 1-year posttreatment had a significant association with the CR of the second posttreatment year, (p = 0.028, OR 0.79; 95 % CI 0.63-0.98) and a similar trend was observed for the following years. These findings emphasize the sustained impact of ETN in the achievement of CR. A low JADAS71 score 1-year posttreatment, may be associated with the maintenance of CR over the next treatment year.

• 出版日期2013-8